Natecal d 1.500 mg/400 ui comprimidos masticables

Patient Information Leaflet

Natecal D1,500 mg/400 IU chewable tablets

(calcium carbonate/vitamin D)

Read this leaflet carefully before you start taking this medicine, as it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, consult your doctor, pharmacist or nurse.
• This medicine has been prescribed for you only, and you must not give it to others even if they have the same symptoms as you, as it may harm them.
• If you experience any side effects, consult your doctor, pharmacist or nurse, even if they are not listed in this leaflet. See section 4.

1. Storage ofNatecal D
2. Contents of the pack and additional information

This medication is an association of calcium and vitamin D.

Natecal D is indicated for the treatment of vitamin D deficiency states in patients who require calcium supplementation, as well as a vitamin D and calcium supplement associated with certain osteoporosis treatments.

Do not take Natecal D

• if you are allergic to calcium, vitamin D, or any of the other components of this medication (listed in section 6).
• if you have kidney stones.
• if you have high levels of calcium in your blood or urine.
• this medication contains soy oil. Do not use in case of allergy to peanuts or soy.

Warnings and precautions

Consult your doctor, pharmacist, or nurse before starting to take Natecal D

• during prolonged treatment with this medication; your doctor will monitor your calcium levels in urine and adjust the dose.
• if your kidneys do not function well or you are prone to forming kidney stones.
• in elderly patients, it is recommended to regularly monitor kidney function.
• if you have sarcoidosis (a disease in which the lymph nodes, lungs, liver, eyes, skin, and other tissues become inflamed).

Other medications and Natecal D

Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.

Certain medications may interact with this medication; in these cases, it may be necessary to change the dose, discontinue treatment with one of them, or wait at least a few hours between administration of both.

It is essential to inform your doctor if you are taking or have taken recently any of the following medications:

• Cardiac glycosides (heart medications).
• Tetracyclines (certain antibiotics), wait at least 3 hours.
• Thiazide diuretics (medications that increase the elimination of water and sodium).
• Anticonvulsants (medications for treating seizures).
• Systemic corticosteroids (medications used as anti-inflammatory agents in various diseases).
• Bisphosphonates and sodium fluoride (medications for treating osteoporosis), wait at least 3 hours.
• Barbiturates (medications that induce sleep) or phenytoin (medication for treating epilepsy).

Taking Natecal D with food, drinks, and alcohol

If you take this medication with foods and drinks containing oxalic acid (present in spinach and rhubarb) or phytic acid (present in whole wheat bread and whole grain cereals), interactions may occur, so it is recommended not to take this medication during the two hours following the consumption of foods with high oxalic acid and phytic acid content.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

The consumption of medications during pregnancy can be hazardous to the embryo and fetus.

During pregnancy and breastfeeding, the daily intake should not exceed 1,500 mg of calcium and 600 IU of vitamin D3.

In pregnant women, excessive doses of vitamin D should be avoided, as maintaining high levels of calcium in the blood for an extended period could cause alterations in the fetus.

Driving and operating machinery

No effects on the ability to drive and operate machinery have been observed.

Natecal D contains sorbitol, aspartame, lactose, sucrose, and sodium

This medication contains 565.25 mg of sorbitol in each 232.04 mg/g equivalent tablet.

Sorbitol is a source of fructose. If your doctor has indicated that you (or your child) suffer from intolerance to certain sugars, or have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disease in which the patient cannot break down fructose, consult your doctor (or your child) before taking this medication.

This medication contains 5.00 mg of aspartame in each 2.05 mg/g equivalent tablet.

Aspartame contains a source of phenylalanine, which may be harmful in cases of phenylketonuria (PKU), a rare genetic disease in which phenylalanine accumulates due to the body's inability to eliminate it correctly.

This medication contains lactose. If your doctor has indicated that you suffer from intolerance to certain sugars, consult with them before taking this medication.

This medication contains sucrose. If your doctor has indicated that you suffer from intolerance to certain sugars, consult with them before taking this medication. It may cause tooth decay.

This medication contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially "sodium-free".

Interactions with diagnostic tests

If you are to undergo any diagnostic test (blood, urine...), inform your doctor that you are being treated with Natecal D, as it may alter the results.

Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

Remember to take your medication. The recommended dose is:

Adults:1-2 chewable tablets per day, preferably after meals.

Use in children and adolescents

Consult your doctor to individualize the dose.

To properly administer the medication, chew the tablets well before swallowing, followed by a glass of water.

If you estimate that the effect of this medication is too strong or too weak, inform your doctor or pharmacist.

If you take moreNatecal Dthan you should

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562.04.20, indicating the medication and the amount ingested.

If you have taken more Natecal D than you should, consult your doctor or pharmacist immediately.

Intentional or accidental overdose with chewable preparations is unlikely.

In case of overdose, you may experience a sensation of thirst, increased levels of calcium in the blood, increased levels of calcium in urine, anorexia, nausea, vomiting, abnormal excretion of large amounts of urine, and calcium deposits in soft tissues.

If you forgot to take Natecal D

Do not take a double dose to compensate for the missed doses, simply take the missed dose when you remember and take the next doses with the indicated interval (12 – 24 hours).

If you have any other questions about the use of this medication, ask your doctor or pharmacist.

Like all medications,this medicationmay produce adverse effects, although not everyone will experience them.

The following adverse effects have been observed:

Rare(may affect up to 1 in 100 people): hypercalcemia (elevated blood calcium levels) and hypercalciuria (elevated calcium levels in urine).

Uncommon(may affect up to 1 in 1,000 people): constipation, gas, nausea, abdominal pain, and diarrhea.

Occasionally, mild digestive disturbances may occur. Natecal D may stimulate the formation of kidney stones in patients with altered renal function.

If you consider any of the adverse effects you are experiencing to be severe or if you notice any adverse effect not mentioned in this leaflet, inform your doctor or pharmacist.

Reporting Adverse Effects

If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.

Keepthis medicationout of the sight and reach of children.

Store in the original packaging to protect it from moisture.

Do not use this medication after the expiration date that appears on the packagingafter “CAD”. The expiration date is the last day of the month indicated.

Medications should not be disposed of through drains or in the trash. Dispose of packaging and unused medications at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.

Composition of Natecal D

The active principles are calcium carbonate and colecalciferol (vitamin D3).

Each tablet contains 1,500 mg of calcium carbonate (equivalent to 600 mg of calcium) and 400 IU of colecalciferol (vitamin D3) (equivalent to 0.01 mg).

The other components (excipients) are: sorbitol (E420), maltodextrin, lactose monohydrate, magnesium stearate, sodium croscarmellose, anise essence, peppermint essence, molasses essence, aspartame (E951), sodium saccharin, sucrose, gelatin, cornstarch, partially hydrogenated soybean oil, all-rac-α-tocopherol, and silicon dioxide.

Appearance of the product and content of the packaging

Natecal Dis presented in the form of chewable tablets, white or almost white in color, marked with a D on one of its faces.

Each package contains 60 chewable tablets.

Holder of the marketing authorization

Italfarmaco, S.A.

C/ San Rafael, 3

28108 Alcobendas, Madrid

Spain

Responsible for manufacturing

ITALFARMACO S.p.A.

Viale Fulvio Testi, 330

20126 Milan

Italy

Last review date of this prospectus:August 2024

The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es).